RKDA — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-13

• Research and development expenses consist of costs incurred in the development and testing of our products. These expenses currently consist primarily of fees paid to product formulation consultants and are expensed as incurred. Additionally, the Company is required from time to time to make certain…

• Credit loss consists of a reserve established related to the Above Food note receivable.

• Other (loss) income, net consists primarily of unrealized loss recognized subsequent to the receipt of the AFII common stock.

• Valuation loss on June 2026 PIPE includes the fair value in excess of gross proceeds.

• Product revenues, which consisted 100% of revenues from the sale of our Zola products, decreased $12,000, or 1%, during the three months ended June 30, 2026 compared to the same period in 2025. The decrease was primarily driven by lower sales volumes as well as low inventory and longer than expected…

Text removed vs the prior filing · source: 10-Q · 2026-05-14

• Other loss, net consists primarily of unrealized loss recognized subsequent to the receipt of the AFII common stock.

• Comparison of the Three Months Ended March 31, 2026 and 2025

• Product revenues, which consisted 100% of Zola, decreased $100,000, or 8%, during the three months ended March 31, 2026 compared to the same period in 2025 driven primarily by a revenue reserve release of approximately $193,000 in 2025 that was absent in 2026.

• During the three months ended March 31, 2025, the Company realized a gain of $750,000 related to the sale of our reduced gluten and oxidative stability patent portfolios. There was no such gain recognized during the three months ended March 31, 2026.

• During the three months ended March 31, 2026, the Company recognized interest income of $5,000. During the three months ended March 31, 2025, the Company recognized interest income of $207,000, of which $180,000 was related to discount amortization and accrued interest on the promissory note from Ab…

Text added vs the prior filing · source: 10-Q · 2026-08-13

• Arcadia’s failure to meet the continued listing requirements of Nasdaq could result in a delisting of its common stock, which could negatively impact the market price and liquidity of its common stock and its ability to access the capital markets.

• Our common stock is listed on the Nasdaq Capital Market. If we fail to satisfy the continued listing requirements of The Nasdaq Stock Market LLC (“Nasdaq”), such as the corporate governance, minimum stockholders equity or minimum closing bid price requirements, Nasdaq may take steps to delist our co…

• On July 22, 2026, the staff of the Securities and Exchange Commission (the “SEC” or the “Commission”), acting pursuant to delegated authority, approved a new listing rule change originally proposed by Nasdaq earlier in 2026 and subsequently amended, requiring listed companies to maintain a minimum M…

• Following approval, the rule originally became effective commencing July 23, 2026. However, because the approval was issued by the staff of the SEC under delegated authority rather than by the Commission itself, on July 29, 2026, the SEC notified Nasdaq that the Commission had received notices of in…

• Our MVLS as of August 13, 2026, was less than the Minimum MVLS. Accordingly, if the new rules were to become effective in the form proposed by Nasdaq and the MVLS of our common stock does not increase sufficiently (as a result of increases in the trading prices of our common stock and/or an increase…